utidelone
Commercial- Indications
- Metastatic breast cancer
Company intelligence / Profile preview
Zhejiang Biostar Biotechnology
Beijing, -, Chinabiostar-pharm.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Commercialized utidelone injectable (2021 NMPA approval) with Phase III trials showing improved PFS/OS in metastatic breast cancer. Currently expanding into oral formulations and new indications.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugAntibody-drug conjugate (ADC)Nano-formulation
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Luye PharmaNovotech
Beyond the preview
Go deeper on Zhejiang Biostar Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Biostar Biotechnology.